Target

IL-2 receptor

4 products, 5 indications

Indications

metastatic melanoma (1 products)

metastatic cutaneous melanoma (1 products)

neuroblastoma (1 products)

Ovarian Cancer (1 products)

Early stage epithelial ovarian cancer (1 products)

2 drugs

5 abstracts

Abstract

Preclinical assessment of IPH6501, a first-in-class IL2v-armed tetraspecific NK cell engager directed against CD20 for R/R B-NHL, in comparison with a CD20-targeting T cell engager.

Org: CIML,

Abstract

The promising feeder-free allogenic NK cell therapy: Clinical outcomes of GIC-102 monotherapy (GIC-102101) and synergistic potential with GI-101 (CD80-IgG4 Fc-IL2v) in advanced solid tumors and hematologic malignancies.

Org: GI Cell, GI Innovation,

Abstract

IOV-3001, a modified interleukin-2 fusion protein, for potential use in tumor-infiltrating lymphocyte cell therapy regimens.

Org: Iovance Biotherapeutics, H. Lee Moffitt Cancer Center and Research Institute,

Abstract

Effect of a novel anti-PD-1-proIL-2 bifunctional fusion protein on potent anti-tumor activity via PD-1 checkpoint inhibition and conditional IL-2R agonism.

Org: Proviva Therapeutics, Bedford, MA, Shanghai, China, Gracell Biotechnologies, Ltd.,

Abstract

Trial START-001: A phase 1/2 study of STAR0602, a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors post checkpoint inhibitor (CPI) treatment.

Org: Marengo Therapeutics, Center for Immuno-Oncology, CCR, NCI, NIH, Center for Immuno-Oncology, CCR, NCI, NIH, Gustave Roussy Cancer Campus, Department of Surgery, Massachusetts General Hospital, Harvard Medical School,

Drug

IL-2

Drug

Nemvaleukin